公开(公告)号：US10995126B2

公开(公告)日：2021-05-04

申请号：US16098735

申请日：2017-05-03

申请人： National Health Research Institutes ,  Academia Sinica

发明人： Shih-Jen Liu ,  Hsin-Wei Chen ,  Steve Roffler ,  Ming-Hsi Huang ,  Chih-Hsiang Leng

IPC分类号： A61K38/00 ,  C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  A61K39/39

摘要： Described herein are an immunogenic peptide containing the sequence of CLDSLGQWN (SEQ ID NO:2) and a method of using the peptide for treating cancer.

公开(公告)号：US10604747B2

公开(公告)日：2020-03-31

申请号：US15750753

申请日：2016-08-05

申请人： Academia Sinica

发明人： Steve Roffler ,  Huai-Yao Chuang

IPC分类号： C12N9/24 ,  C12Q1/40 ,  A61K38/00

摘要： An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.

公开(公告)号：US20180346896A1

公开(公告)日：2018-12-06

申请号：US15750753

申请日：2016-08-05

申请人： Academia Sinica

发明人： Steve Roffler ,  Huai-Yao Chuang

IPC分类号： C12N9/24 ,  C12Q1/40

CPC分类号： C12N9/24 ,  A61K38/00 ,  C12Y302/01031 ,  C12Y302/01076

摘要： An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.

公开(公告)号：US10912832B2

公开(公告)日：2021-02-09

申请号：US16697810

申请日：2019-11-27

申请人： Academia Sinica

发明人： Patrick C. H. Hsieh ,  Pei-Jung Wu ,  Steve Roffler ,  Bill Cheng

IPC分类号： A61K39/395 ,  C07K16/44 ,  A61K9/00 ,  A61K47/36 ,  A61K47/42 ,  A61K47/68 ,  A61K47/60 ,  A61K9/06 ,  A61K38/00

摘要： Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

公开(公告)号：US10532097B2

公开(公告)日：2020-01-14

申请号：US15325346

申请日：2015-07-10

申请人： Academia Sinica

发明人： Patrick C. H. Hsieh ,  Pei-Jung Wu ,  Steve Roffler ,  Bill Cheng

IPC分类号： A61K39/395 ,  C07K16/44 ,  A61K9/00 ,  A61K47/36 ,  A61K47/42 ,  A61K9/06 ,  A61K47/60 ,  A61K47/68 ,  A61K38/00

摘要： Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.